Financial releases | Drupal

2024/12/09

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Read the release

2024/11/13

Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions

Read the release

2024/10/22

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

Read the release

2024/09/26

Crossject confirms its eligibility for France’s PEA-PME investment scheme

Read the release

2024/09/23

Crossject reports financial results and business highlights for the first six months of 2024

Read the release

2024/09/17

Crossject to report first-half 2024 financial results and host webcast on September 23, 2024

Read the release

2024/08/22

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Read the release

2024/08/19

Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment

Read the release

2024/07/18

Crossject achieves key ZEPIZURE® manufacturing milestone

Read the release

2024/07/15

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference

Read the release